Skip to main content

Table 3 The laboratory findings and medical therapy in JSLE patients

From: Long noncoding RNAs (CTC-471J1.2, NeST) as epigenetic risk factors of active juvenile lupus nephritis: a case-control study

Laboratory findings/Medical therapy

JSLE (n = 61)

24h urine protein (gm/dl): (median (range))

0.18 (0.1–5)

Serum creatinine (mg/dL): (mean ± SD)

0.64 ± 0.21

ESR (mm/hour): (mean ± SD)

36 ± 21.7

Complement (mg/dL): (mean ± SD)

98.4 ± 25.8

Anti-dsDNA (IU/mL): (mean ± SD)

548 ± 380.3

Anemia (< 10 g/dl): n (%)

 No

48 (78.7)

 Yes

13 (21.3)

Leucopenia (< 5 × 103/ µL): n (%)

 No

58 (95)

 Yes

3 (5)

Thrombocytopenia (< 150 × 10 3/µL): n (%)

 No

59 (96.7)

 Yes

2 (3.3)

Elevated liver enzymes: n (%)

 No

56 (92)

 Yes

5 (8)

APL antibodies: n (%)

 Negative

50 (82)

 Positive

11 (18)

Medications: n (%)

 Steroid + Hydroxychloroquine

18 (29.5)

 Steroid + Hydroxychloroquine + CYC

17 (27.9)

 Steroid + Hydroxychloroquine + MMF

9 (14.8)

 Steroid + Hydroxychloroquine + CYC + MMF

17 (27.9)

  1. Values reported as median (range), percentile, and mean ± SD
  2. Abbreviations: n Number, SLE Juvenile Systemic Lupus Erythematosus, ESR Erythrocyte Sedimentation Rate, APL Anti-phospholipid Antibodies, CYC Cyclophosphamide, MMF Mycophenolate Mofetil